Offering the Appropriate Patient the Opportunity for Treatment with TRK Inhibitors

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.

Related Videos

September 2, 2015

Changing the Way Takeda Oncology Develops Cancer Medicines

Dixie-Lee Esseltine, MD and George Mulligan, PhD offer insight on the impact of ixazomib on Takeda Oncology’s approach to multiple myeloma care and its approach to other cancer types.

December 12, 2016

Clinical Management for Relapsing Patients

Sunil Verma, MD, MSEd, FRCPC discusses all the patient factors when managing patients who relapse.